Clinical trial · Observational
Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer
NCT02075957CI-TRIAL-00013926SITRRunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Description of new transcriptional profiles associated with risk of relapse and identification of specific sites of relapse in non-small cell lung cancer, toxicity and resistance to adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (11)
- measure
- Determination of news microarrays profiles of NSCLC relapse risks
- timeFrame
- 6 to 8 weeks after surgery
- description
- The news microarrays profiles of NSCLC relapse risks will : * assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) * assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient * assessing the prediction of sites most likely metastatic relapse to guide survey strategy.
- measure
- Determination of news microarrays profiles of NSCLC relapse risks
- timeFrame
- At 1 year
- description
- The news microarrays profiles of NSCLC relapse risks will : * assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) * assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient * assessing the prediction of sites most likely metastatic relapse to guide survey strategy.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Major subject * Subject who received resection with primary non-small cell lung cancer at the University Hospital of Angers and whose tumor samples will be stored in collection of biological resources of University Hospital of Angers * A written inform consent. Exclusion Criteria: * Under 18 year old; * Pregnant or nursing women; * Deprived of liberty; * Age under curatorship or guardianship; * Unable to consent person; * About not carrying a non-small cell lung cancer.
References
Publications (0)
Data not yet available
No reference posted for this study.